Literature DB >> 8585008

Haemostatic effects of supraphysiological levels of testosterone in normal men.

R A Anderson1, C A Ludlam, F C Wu.   

Abstract

The effects of exogenous testosterone on the haemostatic system were studied in a group of 32 healthy men undergoing a clinical trial of hormonal male contraception. The men received 200 mg testosterone oenanthate (TE) weekly i.m., and plasma samples were taken pretreatment, at defined time points up to 52 weeks of treatment, and 4 and 8 weeks after discontinuing TE. This dose of TE caused a 2-fold increase in trough plasma testosterone levels. TE caused a fall in plasma fibrinogen concentration after 16 weeks of treatment. This was sustained for the duration of TE treatment and recovered to pretreatment levels during the recovery phase. There was also a sustained fall in the level of C4b binding protein which showed a rebound to levels above pretreatment during recovery. Levels of antithrombin III and prothrombin fragment F1.2 rose initially during TE treatment, and levels of protein C, protein S (free) and plasminogen activator inhibitor fell, but the concentrations of these factors all returned to pretreatment levels during continued treatment. There was no change in the plasma concentrations of beta-thromboglobulin, tissue plasminogen activator, protein S (total), or D-dimer. There was a sustained increase in haemoglobin concentration and haematocrit, without any change in platelet count. The observed changes were consistent with mild activation of the haemostatic system during initial treatment with testosterone. After several months the raised activation markers had returned to pretreatment levels indicating that a new equilibrium had been established which did not appear to be prothrombotic.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8585008

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Four Thrombotic Events Over 5 Years, Two Pulmonary Emboli and Two Deep Venous Thrombosis, When Testosterone-HCG Therapy Was Continued Despite Concurrent Anticoagulation in a 55-Year-Old Man With Lupus Anticoagulant.

Authors:  Charles J Glueck; Kevin Lee; Marloe Prince; Vybhav Jetty; Parth Shah; Ping Wang
Journal:  J Investig Med High Impact Case Rep       Date:  2016-08-01

2.  Evolution of testosterone treatment over 25 years: symptom responses, endocrine profiles and cardiovascular changes.

Authors:  Malcolm Carruthers; Paul Cathcart; Mark R Feneley
Journal:  Aging Male       Date:  2015-07-28       Impact factor: 5.892

3.  Sex-related differences in the association between plasma fibrinogen and non-calcified or mixed coronary atherosclerotic plaques.

Authors:  Tiewei Li; Fang Wang; Rui Peng; Shengqiang Pei; Zhihui Hou; Bin Lu; Xiangfeng Cong; Xi Chen
Journal:  Biol Sex Differ       Date:  2018-12-05       Impact factor: 5.027

Review 4.  Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention?

Authors:  Dheeraj Kapoor; T Hugh Jones
Journal:  Drugs Aging       Date:  2008       Impact factor: 4.271

Review 5.  Testosterone for the aging male; current evidence and recommended practice.

Authors:  Roger D Stanworth; T Hugh Jones
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

6.  Effect of taking dietary supplement on hematological and biochemical parameters in male bodybuilders an equation model.

Authors:  Rokhsareh Meamar; Mohammad Maracy; Shahrzad Nematollahi; Shemouil Yeroshalmi; Ali Zamani-Moghaddam; Mohammad Reza Aghaye Ghazvini
Journal:  Iran J Nurs Midwifery Res       Date:  2015 Nov-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.